.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Site of Chemotherapy Administration Impacts Spending: An Interview With Yamini Kalidindi

Published on: July 17, 2018

There are concerns that cancer care costs may increase as the site of provider-administered cancer drugs shifts from physician offices to hospital outpatient departments. The lead author of a July paper explains why the findings of her study differ from previous research and highlights the importance of considering patient characteristics.

There are concerns that cancer care costs may increase as the site of provider-administered cancer drugs shifts from physician offices to hospital outpatient departments. Researchers in the July issue of The American Journal of Managed Care^® examined chemotherapy-related spending in Medicare Part B after controlling for patient characteristics, such as cancer type, and explored differences in chemotherapy utilization patterns between the 2 settings.

In this interview, lead author Yamini Kalidindi, a research assistant at Pennsylvania State University and a graduate student in the department of health policy and administration, explains why the findings of her study differ from previous research and highlights the importance of considering patient characteristics such as cancer type.

To listen, login to the website.

Differences in Spending on Provider-Administered Chemotherapy by Site of Care in Medicare

iTunes: http://apple.co/2eYWTss

TuneIn: http://bit.ly/2gv7iwj

Stitcher: http://bit.ly/2gCqtFg

Read the paper in the July issue:Listen above or through one of these podcast services: